Myriad Genetics Inc (MYGN) 32.06 $MYGN
Myriad Announces Positive Results for an EndoPredict(R) Clinical Study Published in the Journal of the National Cancer Institute
Globe Newswire - Mon Jul 11, 10:46AM CDT
"EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX(R)) Across the 10-Year Follow-up Period" in a Large Head-to-Head Breast Cancer Study
MYGN: 32.06 (+0.37)
Myriad Genetics myChoice Cancer Test Findings Encourage
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:34AM CDT
With respect to myChoice HRD test, Myriad earlier noted that it expects to serve a worldwide market size of $18.5 billion (compared with the current market size of $5.6 billion).
MYGN: 32.06 (+0.37), TSRO: 88.20 (-0.50), HSKA: 43.50 (-0.02), INVA: 11.77 (+0.13)
Myriad Genetics: Study Data Drives Growth, Competition Rife
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:51AM CDT
Most recent study data from the Nova trial shows Myriad's (MYGN) myChoice HRD test's effectiveness in detecting an increased number of ovarian cancer patients
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), MYGN: 32.06 (+0.37), LMAT: 13.64 (-0.06)
Look for Shares of Myriad Genetics to Potentially Pullback after Yesterday's 1.63% Rise
Comtex SmarTrend(R) - Wed Jun 22, 2:33PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $30.55 to a high of $32.00. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $31.60 on volume of 597,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 32.06 (+0.37)
Global DNA Repair Drugs Report: Focus on PARP Inhibitors 2016-2026 - Myriad Genetics and Foundation Medicine Have Emerged as the Major Diagnostic Developers - Research and Markets
PR Newswire Europe - Wed Jun 22, 7:11AM CDT
DUBLIN, June 22, 2016 /PRNewswire/ --
MYGN: 32.06 (+0.37)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 32.06 (+0.37), BAH: 30.18 (+0.40), INCR: 40.27 (+0.70), QGEN: 22.04 (-0.11)
Crescendo Bioscience Announces that New Data on Vectra(R) DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress
GlobeNewswire - Fri Jun 10, 6:05AM CDT
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA test to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at European League Against Rheumatism (EULAR) meeting being held June 8-11, 2016, in London. Vectra DA test is the first and only multi-biomarker blood test validated to measure disease activity in patients with RA and has been evaluated in multiple studies, resulting in 23 scientific peer-reviewed publications.
MYGN: 32.06 (+0.37)
Myriad Board Approves $200 Million Increase in Share Repurchase Program
GlobeNewswire - Tue Jun 07, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Company had repurchased greater than $1.1 billion of stock since the inception of the program in 2010 at an average share price of $26.16.
MYGN: 32.06 (+0.37)
Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:00 a.m. Pacific on June 8, 2016, at the Terranea Resort in Rancho Palos Verdes, California.
MYGN: 32.06 (+0.37)
Myriad myRisk(R) Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk Hereditary Cancer test will be featured in oral presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the importance of using a 25-gene panel to evaluate risk for hereditary breast and ovarian cancers.
MYGN: 32.06 (+0.37)
Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk Hereditary Cancer test will be featured in podium presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the expanding benefits of gene panel testing and underscore the need for gene panel testing to become the standard-of-care for hereditary cancer risk evaluation.
MYGN: 32.06 (+0.37)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), MYGN: 32.06 (+0.37), BAX: 46.49 (-0.16)
After Yesterday's Rally of 1.25% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:53PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $34.27 to a high of $34.78. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.49 on volume of 779,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 32.06 (+0.37)
Myriad Acquires Sividon Diagnostics
Globe Newswire - Tue May 31, 3:05PM CDT
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict(R)
MYGN: 32.06 (+0.37)
Watch for Myriad Genetics to Potentially Rebound After Falling 2.83% Yesterday
Comtex SmarTrend(R) - Thu May 26, 3:24PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 32.06 (+0.37)
After Yesterday's Decline of 2.83%, Myriad Genetics Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 26, 3:22PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 32.06 (+0.37)
Myriad Genetics' Statement on HIPAA Complaint from Four Patients
GlobeNewswire - Thu May 19, 3:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. The Company believes it has complied with these requests and provided these four patients with their designated record set and all requested personal health information. Therefore, we believe the complaint lacks merit and should not be accepted.
MYGN: 32.06 (+0.37)
Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information
GlobeNewswire - Wed May 18, 4:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.
MYGN: 32.06 (+0.37)
Myriad Announces Positive Results for an EndoPredict(R) Clinical Study Published in the Journal of the National Cancer Institute
Globe Newswire - Mon Jul 11, 10:46AM CDT
"EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX(R)) Across the 10-Year Follow-up Period" in a Large Head-to-Head Breast Cancer Study
MYGN: 32.06 (+0.37)
Myriad Genetics myChoice Cancer Test Findings Encourage
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:34AM CDT
With respect to myChoice HRD test, Myriad earlier noted that it expects to serve a worldwide market size of $18.5 billion (compared with the current market size of $5.6 billion).
MYGN: 32.06 (+0.37), TSRO: 88.20 (-0.50), HSKA: 43.50 (-0.02), INVA: 11.77 (+0.13)
Myriad Genetics: Study Data Drives Growth, Competition Rife
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:51AM CDT
Most recent study data from the Nova trial shows Myriad's (MYGN) myChoice HRD test's effectiveness in detecting an increased number of ovarian cancer patients
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), MYGN: 32.06 (+0.37), LMAT: 13.64 (-0.06)
Look for Shares of Myriad Genetics to Potentially Pullback after Yesterday's 1.63% Rise
Comtex SmarTrend(R) - Wed Jun 22, 2:33PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $30.55 to a high of $32.00. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $31.60 on volume of 597,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 32.06 (+0.37)
Global DNA Repair Drugs Report: Focus on PARP Inhibitors 2016-2026 - Myriad Genetics and Foundation Medicine Have Emerged as the Major Diagnostic Developers - Research and Markets
PR Newswire Europe - Wed Jun 22, 7:11AM CDT
DUBLIN, June 22, 2016 /PRNewswire/ --
MYGN: 32.06 (+0.37)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 32.06 (+0.37), BAH: 30.18 (+0.40), INCR: 40.27 (+0.70), QGEN: 22.04 (-0.11)
Crescendo Bioscience Announces that New Data on Vectra(R) DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress
GlobeNewswire - Fri Jun 10, 6:05AM CDT
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA test to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at European League Against Rheumatism (EULAR) meeting being held June 8-11, 2016, in London. Vectra DA test is the first and only multi-biomarker blood test validated to measure disease activity in patients with RA and has been evaluated in multiple studies, resulting in 23 scientific peer-reviewed publications.
MYGN: 32.06 (+0.37)
Myriad Board Approves $200 Million Increase in Share Repurchase Program
GlobeNewswire - Tue Jun 07, 6:05AM CDT
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Company had repurchased greater than $1.1 billion of stock since the inception of the program in 2010 at an average share price of $26.16.
MYGN: 32.06 (+0.37)
Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:00 a.m. Pacific on June 8, 2016, at the Terranea Resort in Rancho Palos Verdes, California.
MYGN: 32.06 (+0.37)
Myriad myRisk(R) Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients
GlobeNewswire - Mon Jun 06, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk Hereditary Cancer test will be featured in oral presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the importance of using a 25-gene panel to evaluate risk for hereditary breast and ovarian cancers.
MYGN: 32.06 (+0.37)
Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 6:05AM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk Hereditary Cancer test will be featured in podium presentations at the 2016 American Society of Clinical Oncology annual meeting. These presentations demonstrate the expanding benefits of gene panel testing and underscore the need for gene panel testing to become the standard-of-care for hereditary cancer risk evaluation.
MYGN: 32.06 (+0.37)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), MYGN: 32.06 (+0.37), BAX: 46.49 (-0.16)
After Yesterday's Rally of 1.25% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:53PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $34.27 to a high of $34.78. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.49 on volume of 779,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 32.06 (+0.37)
Myriad Acquires Sividon Diagnostics
Globe Newswire - Tue May 31, 3:05PM CDT
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict(R)
MYGN: 32.06 (+0.37)
Watch for Myriad Genetics to Potentially Rebound After Falling 2.83% Yesterday
Comtex SmarTrend(R) - Thu May 26, 3:24PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 32.06 (+0.37)
After Yesterday's Decline of 2.83%, Myriad Genetics Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 26, 3:22PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $33.92 to a high of $35.13. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $34.01 on volume of 363,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYGN: 32.06 (+0.37)
Myriad Genetics' Statement on HIPAA Complaint from Four Patients
GlobeNewswire - Thu May 19, 3:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. The Company believes it has complied with these requests and provided these four patients with their designated record set and all requested personal health information. Therefore, we believe the complaint lacks merit and should not be accepted.
MYGN: 32.06 (+0.37)
Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information
GlobeNewswire - Wed May 18, 4:56PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.
MYGN: 32.06 (+0.37)
